» Articles » PMID: 32477070

Cytoplasmic TDP43 Binds MicroRNAs: New Disease Targets in Amyotrophic Lateral Sclerosis

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive, fatal, and incurable neurodegenerative disease. Recent studies suggest that dysregulation of gene expression by microRNAs (miRNAs) may play an important role in ALS pathogenesis. The reversible nature of this dysregulation makes miRNAs attractive pharmacological targets and a potential therapeutic avenue. Under physiological conditions, miRNA biogenesis, which begins in the nucleus and includes further maturation in the cytoplasm, involves trans-activation response element DNA/RNA-binding protein of 43 kDa (TDP43). However, TDP43 mutations or stress trigger TDP43 mislocalization and inclusion formation, a hallmark of most ALS cases, that may lead to aberrant protein/miRNA interactions in the cytoplasm. Herein, we demonstrated that TDP43 exhibits differential binding affinity for select miRNAs, which prompted us to profile miRNAs that preferentially bind cytoplasmic TDP43. Using cellular models expressing TDP43 variants and miRNA profiling analyses, we identified differential levels of 65 cytoplasmic TDP43-associated miRNAs. Of these, approximately 30% exhibited levels that differed by more than 3-fold in the cytoplasmic TDP43 models relative to our control model. The hits included both novel miRNAs and miRNAs previously associated with ALS that potentially regulate several predicted genes and pathways that may be important for pathogenesis. Accordingly, these findings highlight specific miRNAs that may shed light on relevant disease pathways and could represent potential biomarkers and reversible treatment targets for ALS.

Citing Articles

Systematic review and meta-analysis of dysregulated microRNAs derived from liquid biopsies as biomarkers for amyotrophic lateral sclerosis.

Casado Gama H, Amoros M, de Araujo M, Sha C, Vieira M, Torres R Noncoding RNA Res. 2024; 9(2):523-535.

PMID: 38511059 PMC: 10950706. DOI: 10.1016/j.ncrna.2024.02.006.


TDP-43 protein interactome informs about perturbed canonical pathways and may help develop personalized medicine approaches for patients with TDP-43 pathology.

Helmold B, Pauss K, Ozdinler P Drug Discov Today. 2023; 28(11):103769.

PMID: 37714405 PMC: 10872580. DOI: 10.1016/j.drudis.2023.103769.


RNA-binding proteins as a common ground for neurodegeneration and inflammation in amyotrophic lateral sclerosis and multiple sclerosis.

Acosta-Galeana I, Hernandez-Martinez R, Reyes-Cruz T, Chiquete E, Aceves-Buendia J Front Mol Neurosci. 2023; 16:1193636.

PMID: 37475885 PMC: 10355071. DOI: 10.3389/fnmol.2023.1193636.


Looking for answers far away from the soma-the (un)known axonal functions of TDP-43, and their contribution to early NMJ disruption in ALS.

Ionescu A, Altman T, Perlson E Mol Neurodegener. 2023; 18(1):35.

PMID: 37259156 PMC: 10233987. DOI: 10.1186/s13024-023-00623-6.


Implications of miRNAs dysregulation in amyotrophic lateral sclerosis: Challenging for clinical applications.

Koike Y, Onodera O Front Neurosci. 2023; 17:1131758.

PMID: 36895420 PMC: 9989161. DOI: 10.3389/fnins.2023.1131758.


References
1.
Vlachos I, Zagganas K, Paraskevopoulou M, Georgakilas G, Karagkouni D, Vergoulis T . DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res. 2015; 43(W1):W460-6. PMC: 4489228. DOI: 10.1093/nar/gkv403. View

2.
Hollville E, Romero S, Deshmukh M . Apoptotic cell death regulation in neurons. FEBS J. 2019; 286(17):3276-3298. PMC: 6718311. DOI: 10.1111/febs.14970. View

3.
MBoutchou M, van Kempen L . Analysis of the Tumor Microenvironment Transcriptome via NanoString mRNA and miRNA Expression Profiling. Methods Mol Biol. 2016; 1458:291-310. DOI: 10.1007/978-1-4939-3801-8_21. View

4.
Wegorzewska I, Baloh R . TDP-43-based animal models of neurodegeneration: new insights into ALS pathology and pathophysiology. Neurodegener Dis. 2010; 8(4):262-74. PMC: 3214943. DOI: 10.1159/000321547. View

5.
Poddar S, Kesharwani D, Datta M . Interplay between the miRNome and the epigenetic machinery: Implications in health and disease. J Cell Physiol. 2017; 232(11):2938-2945. DOI: 10.1002/jcp.25819. View